The histopathology of antibody-mediated rejection in lung allografts, outside of classical hyperacute rejection, has been poorly defined, in part because of the difficulty in identifying potential alloantibodies and in separating alloreactive and nonspecific complement-mediated reactions. In this study, we looked at lung biopsies coinciding with the development of anti-human leukocyte antigen (anti-HLA) antibodies and lung dysfunction in a diverse group of lung transplant recipients over a 3-year period. We identified 23 patients and found that 17 had coexistent high-grade acute cellular rejection, 5 had patchy acute lung injury, and 1 had bronchiolitis at the time that anti-HLA alloantibodies appeared. Capillaritis was seen in 4/22 (18%) cases, usually in the context of cellular rejection. When the 17 cases of acute cellular rejection with coexistent anti-HLA antibodies were compared with a matched group of 26 patients with equivalent cellular rejection grade without anti-HLA antibodies, the only morphologic feature that separated the 2 groups was capillaritis seen in a minority of cases. C4d deposits were seen in both groups, although more frequently in those cases with anti-HLA antibodies (76% vs. 24%). The development of anti-HLA alloantibodies often occurs in the setting of acute cellular rejection, which in only a minority of cases can be identified as likely having an antibody-mediated component. C4d staining does not consistently separate the 2 groups. Identifying and ascribing allograft dysfunction to antibody-mediated rejection related to the development of anti-HLA antibodies is a difficult task that cannot be solved exclusively by morphology and requires significant clinicopathologic correlation.
T he histopathology of acute and chronic rejection of the lung allograft has been well described since the first consensus conference on rejection nomenclature in 1990. 3, 25, 28 The focus of that conference and subsequent ones was on the cellular manifestations of lung rejection primarily in the form of perivascular and alveolar septal mononuclear infiltrates called "acute rejection" and the chronic fibrosing processes affecting the airways and blood vessels labeled bronchiolitis obliterans and accelerated atherosclerosis, respectively. Although attention has been directed at characterizing the nature of the cellular infiltrates and predicting outcome in lung rejection, it has become clear, particularly in cardiac and renal allografts, that the role of antibody-mediated injury in lung allografts needs to be addressed. 25 Certainly there have been several reports of "alveolar septal necrosis" or pulmonary capillaritis with alveolar hemorrhage responsive to plasmapheresis that suggest antibody-induced lung injury, but the supportive evidence for the role of donor-specific antibodies has been weak. 1, [13] [14] [15] [16] [17] [18] 20, 24, 26 Complement deposits, particularly subendothelial deposits of C3d and C4d, have been identified, but such deposits may be seen in any alveolar capillary injury syndrome that activates the classical or mannose binding lectin pathways of the complement cascade, including harvest/reperfusion injury, microbial infection, and high-grade acute cellular rejection with acute lung injury (A3/A4 cellular rejection). 13, 17, 26, 27 Although the development of donor-specific alloantibodies has been studied most often, the presence of antibodies against any cellular component of the lung graft-epithelial cells, endothelial cells, and collagen-has also been hypothesized and complicate the assignment of etiology to the spectrum of morphologic findings of antibody and cellular-mediated rejection. 5, 11, 12, 16, 19 In this study we assessed the clinicopathologic features of allograft lung biopsies at the time of clinical graft dysfunction coinciding with serologic development of anti-donor-specific HLA antibodies and compared them with biopsies of patients matched for postoperative day and cellular rejection grade to determine whether there are morphologic or immunohistochemical findings that would allow us to identify those allograft biopsies with anti-HLA antibody-mediated lung injury.
MATERIALS AND METHODS
Forty-nine lung allograft transbronchial biopsies from 49 patients who had undergone transplantation from 2009 to 2011 at the University of Pittsburgh formed the basis for this study, which was approved by the Institutional Review Board of the University of Pittsburgh Medical Center. All patients received Alemtuzumab depletion (antilymphocyte antibodies) before transplantation, followed by maintenance immunosuppression with FK506/tacrolimus and low-dose steroids. Blood samples were collected before lung transplantation and at the time of transbronchial biopsy procedure and were assessed for IgG, anti-class I, and anti-class II HLAspecific alloantibodies by Luminex single-antigen bead studies (Labscreen, One Lambda; Canoga Park, CA) and analyzed using a Luminex 100LS fluoroanalyzer (Luminex Inc., Austin, TX). [16] [17] [18] Positive reactions were considered when the mean fluorescent intensity was Z1000 or with a clear pattern with mean fluorescent intensity >800. HLA typing of donor and recipient was carried out by standard molecular typing for low resolution using single specific primer-polymerase chain reaction. All patients were complement dependent anti-human globulin augmented (CDC-AHG) cross-match (CXM) negative for T, and only 1 patient was CDC-CXM positive for B cells and exhibited class II donor-specific antibody before transplant.
Twenty-three patients developed anti-HLA antibodies and had transbronchial biopsies available at the time of this development, which coincided with clinical allograft dysfunction and formed the study population. A population of 26 patients matched for age, sex, rejection prevalence, and postoperative day with similar grades of acute cellular rejection without anti-HLA antibodies formed a morphologic control group for the specificity assessment of the morphologic findings occurring in the antibody-positive group. Morphologic features that were studied across the 2 populations included acute cellular rejection grades using the 2007 revised classification focused largely on A and B scores. In addition, the following features were noted: endothelialitis, capillaritis, acute lung injury, eosinophils, large airway inflammation, plasma cells, increased alveolar septal neutrophils, and C4d deposits. Capillaritis was defined as a patchy process of intense septal infiltration by neutrophils associated with neutrophil karyorrhexis and fibrin exudation, with secondary spillover into air spaces, with or without alveolar hemorrhage. In the absence of neutrophil fragmentation and fibrin exudation, the process was interpreted as "neutrophil margination." Endothelialitis was defined as subendothelial infiltration by lymphocytes and plasma cells without destruction of vascular wall components. Acute lung injury manifested as alveolar septal edema with air space fibrin exudation forming hyaline membranes and intra-alveolar granulation tissue plugs adherent to septae.
For each transbronchial biopsy, 3 hematoxylin and eosin stainings, 1 trichrome staining, and 1 Verhoeff Van Gieson elastic tissue staining were performed. Grocott stains and other antimicrobial stains were ordered as appropriate. Immunostaining for C4d was performed as previously described. 14 When present, C4d deposits were assessed for their distribution and presence in the biopsies. A diffuse distribution indicated involvement of >50% of capillaries in all biopsy specimen fragments, whereas a patchy pattern involved <50% of capillaries without involvement of all biopsy fragments, a classification roughly based on prior studies in kidney allografts. The staining of venules and arterioles was not evaluated in lung parenchyma and bronchial submucosa, as this has been interpreted as a nonspecific pattern. Ten negative allograft biopsies served as negative controls, whereas positive controls included heart and kidney biopsies with a known diagnosis of antibody-mediated rejection.
RESULTS
Data resulting from the study of the 23 patients with transbronchial biopsies are shown in Table 1 . The biopsies from those allograft recipients who developed anti-HLA antibodies fell into 3 morphologic categories: (1) those associated with high-grade acute cellular rejection (17/23; 74%); (2) those associated with acute and organizing lung injury (5/23; 22%); and (3) those associated with lymphocytic bronchiolitis (1/23; 4%). Of the 17 patients with acute cellular rejection, 2 were A2/mild, 14 were A3/moderate, and 1 was A4/severe (Figs. 1, 2). Of those with acute cellular rejection, 16/17 (94%) had endothelialitis, and 3/17 (18%) had focal capillaritis without evidence of alveolar hemorrhage. (Fig. 3 ). Eosinophils were commonly seen (14/17; 82%). Similarly, 14/17 (82%) displayed small airway inflammation, which often coincided with a large airway inflammation (15/17, 88%) . When compared with a matched group of patients with high-grade acute cellular rejection ( Table 2) only capillaritis was unique to the alloantibody group.
The second group of patients showed areas of acute and organizing lung injury without perivascular or peribronchiolar lymphocytic infiltrates (5/23; 22%) ( Fig. 4 ). Endothelialitis was noted in 1 of these 5 cases. In these instances, interstitial edema was patchy with alveolar pneumocyte prominence and occasional hyaline membranes or air space granulation tissue.
The last case showed a mild lymphocytic bronchiolitis without perivascular infiltrates or bronchiolitis obliterans.
In the acute cellular rejection group with anti-HLA antibodies, 13/17 (76%) biopsies showed C4d deposits. These deposits were usually focal and difficult to identify because of their patchiness and localized segmental presence in the subendothelial zones of pulmonary capillaries ( Fig. 5 ). Diffuse multifocal linear staining was noted in only 2 cases. In 2 of the 3 cases with alveolar damage, C4d deposits were observed. None were seen in the single case of lymphocytic bronchiolitis. In the matched group of 26 patients without serum anti-HLA antibodies, 6/26 (24%) showed a similar pattern and distribution of C4d deposits. Prior studies by our group have shown that transbronchial biopsies of patients without anti-HLA antibodies with no or minimal acute cellular rejection very rarely, if ever, have C4d deposits.
The characteristics of the donor-specific anti-HLA alloantibodies were interesting. Twenty-two of the 23 patients (96%) were CXM negative at transplant, with only 1 patient having preformed class II (DP) antibody. Of those patients with acute cellular rejection, 88% had class II alloantibodies (13 patients with class II only and 2 with classes I and II), and of those without cellular rejection 5 of 6 (83%) had class I alloantibodies (2 patients with class I only and 3 with classes I and II). Acute cellular rejection was associated with class II donor-specific antibodies in 13/14 (93%) cases, with class I in 2/4 (50%) and classes I and II in 2/5 (40%) patients.
DISCUSSION
The insertion of a solid organ allograft is accompanied by a wide range of immunopathologic responses that are both acute and chronic and involve activation of cellular and antibody-mediated injurious responses. These reactions are complicated in the lung by nonalloreactive factors that can act as initiators or mimickers of donor-specific immunologic responses, including harvest/reperfusion injury, microbial infection, and drug-induced lung injury among others. 6, 21, 22 A major problem in dissecting these causes has been an inability to determine the role of antibody-mediated rejection and its morphologic manifestations in lung allografts. 11 This study was designed to determine whether lung allograft biopsy findings could identify histologic features with or without C4d expression that would allow one to suggest a role of donor-specific anti-HLA antibodies in the lung injury. Using a matched group of lung allografts without donor-specific anti-HLA antibodies, it is clear that the development of these antibodies is associated with the development of high-grade (ZA2) acute cellular rejection in the vast majority of cases. When one compares morphologic findings in acute cellular rejection, the presence of capillaritis appears to be more common in A3 rejection cases with donor-specific anti-HLA antibodies, and yet such capillaritis occurs only in a minority of these instances. Although capillary damage is seen in moderate and severe acute cellular rejection due to lymphohistiocyte-mediated damage, anti-HLA antibodies seem to be associated with neutrophilic damage to the allograft. 4, 25 Rare cases of severe acute rejection have been recognized to have vasculitis/capillaritis, usually with neutrophils attracted by nonspecific complement activation. We suspect that had A4 rejection been more prevalent, capillaritis might have been more common in this study, reducing its specificity. 1, 2, 20 Although capillaritis appears to be a marker for antibody-mediated rejection, in an ongoing study of capillaritis in lung allografts none of the 7 patients with pure capillaritis had donor-specific anti-HLA antibodies, and only 4 of the 7 had C4d deposits (data not shown). These results highlight that there may be other antiallograft antibodies causing vasculitis or that even other causes for capillary damage should be considered, such as sepsis, drug reactions, or new onset or reactivation of native rheumatologic diseases, or that our definition for capillaritis is too nonspecific to be separated from neutrophil margination. The second manifestation of donor-specific anti-HLA-associated allograft lung injury is acute and organizing alveolar damage. This may correspond to the capillary injury described by Magro and colleagues as "alveolar septal necrosis," which they noted was often associated with C4d and C3d deposits. 14, 15 Although these cases were occasionally accompanied by increased septal mononuclear cells and neutrophils, active capillaritis was not seen. As described previously by us, as well as by Westall and Wallace and colleagues, 13, 26, 27 nonimmunologic diffuse alveolar damage in lung allografts is accompanied by subendothelial C4d deposits originating from the mannose binding lectin pathway and is common in allografts affected by infection, sepsis, and hypoperfusion/harvest-reperfusion injury. Diffuse alveolar damage as a manifestation of antibody-mediated rejection would be more likely to be diagnosed after the window of ischemic injury had passed and is most often seen late after transplantation when such a complication is rare.
The role of C4d in the evaluation of acute HLA antibody-mediated rejection must be balanced by the recognition that high-grade acute cellular rejection is accompanied by capillary injury and occasionally by nonallogenic C4d deposits. 13, 21 Although C4d is a sensitive test for antibody-mediated rejection it lacks specificity. 13, 27 There can be multiple explanations for this observation-low sensitivity of immunohistochemical staining, absorption of deposits, or simply low-titer antibody expression. In other organ systems, C4d-negative antibodymediated rejection has been hypothesized and is perhaps tied to unique non-HLA antiallograft antibodies. 5, 21 The clinical presentation of the recipients in this study is of some interest. First, there is a clear biphasic peak to the development of anti-HLA antibodies. An early peak within 90 days may represent an amnestic or reactivation response or could be related to an accelerated B-cell response to the new donor allograft, although in only 2 patients could we demonstrate the presence of low levels of donor-specific anti-HLA antibodies. Interestingly, none of these patients presented with hemoptysis or with an alveolar hemorrhage syndrome and therefore would not fall into a classical hyperacute rejection scenario. A late second peak usually occurring more than a year after transplantation is likely because of the development of new donor-specific antibodies. 8, 29 In both settings, studies at the University of Pittsburgh have shown an association of the development of these alloantibodies with recalcitrant high-grade rejection and with the development of bronchiolitis obliterans. 7, 9, 10 Defining the criteria for and histologic features of antibody-mediated rejection in solid organ allografts has been difficult. 3, 23, 25 This study was not designed to answer this question; however, it does highlight that most patients who develop donor-specific anti-HLA antibodies manifest with high-grade acute cellular rejection. A hint that alloantibodies may be a component of an alloreactive response is the minority of cases with small vessel capillaritis. The second manifestation is diffuse alveolar damage with alveolar septal and capillary damage. Third, the literature clearly notes pure capillaritis as one form of allograft injury that does not fall within the classical spectrum of cellular rejection. Extrapolated from other organ systems-for example, kidney-one would expect an association with autoantibodies, a finding unfortunately not convincingly demonstrated in most of these reports on lung allografts. This may be partly because of the multiple different antidonor antibodies that can develop-for example, antiendothelial antibodies-rather than being restricted to anti-HLA antibodies. Also, capillary damage, capillaritis, and C4d deposits do not necessarily reflect alloreactive injury despite arguments to the contrary and may have multiple other etiologies.
The role of C4d deposits in the assessment of antibody-associated injury is unclear. Many injurious reactions in the lung cause complement deposits in a nonspecific pattern. Although subendothelial C4d is a common finding and could support the presence of antibody-mediated rejection, other etiologies need to be excluded, especially high-grade acute cellular rejection, harvest/reperfusion injury, and infection. No specific pattern of deposit was characteristic. Consequently, C4d staining needs to be interpreted in a very specific clinical context if it is to be used as evidence for therapeutic intervention for antibody-mediated allograft injury.
